Trial Profile
A phase I/II study of UMN-0501 (prepandemic recombinant hemagglutinin influenza vaccine) administrated intramuscularly in healthy, 20 to 40 years of age, male volunteers investigating it's safety, tolerability and immunogenicity. (single center, ascending doses, open label)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Alum
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors UMN Pharma
- 23 Jun 2008 New trial record.